Top 10 developments in lupus nephritis

Teresa K. Chen; Derek M. Fine

doi:10.1007/s11926-013-0358-7

Top 10 developments in lupus nephritis

Teresa K. Chen, Derek M. Fine

School of Medicine

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Lupus nephritis affects up to 60 % of patients with systemic lupus erythematosus and is associated with worse clinical outcomes. Traditionally, it has been treated with high-dose immunosuppression consisting of cyclophosphamide and prednisone; however, recent trials have demonstrated mycophenolate mofetil as a safe and effective alternative for both induction and maintenance of disease. Other progress has been made in our understanding of the pathogenesis of lupus nephritis, outcomes in renal transplantation, and associations with genetic risk factors. This review highlights key developments in our understanding of lupus nephritis over the past decade.

Original language	English (US)
Article number	358
Journal	Current rheumatology reports
Volume	15
Issue number	9
DOIs	https://doi.org/10.1007/s11926-013-0358-7
State	Published - Sep 2013

Keywords

APOL1
Epidemiology
Induction therapy
Kidney
Lupus nephritis
Maintenance therapy
Membranous lupus nephritis
Multitargeted therapy
Mycophenolatemofetil
Proliferative lupus nephritis
Renal transplantation
Rituximab
SLE
Systemic lupus erythematosus
Treatment

ASJC Scopus subject areas

Rheumatology

Access to Document

10.1007/s11926-013-0358-7

Cite this

@article{7c1c9ce0894d46dab3895d37edde0440,

title = "Top 10 developments in lupus nephritis",

abstract = "Lupus nephritis affects up to 60 % of patients with systemic lupus erythematosus and is associated with worse clinical outcomes. Traditionally, it has been treated with high-dose immunosuppression consisting of cyclophosphamide and prednisone; however, recent trials have demonstrated mycophenolate mofetil as a safe and effective alternative for both induction and maintenance of disease. Other progress has been made in our understanding of the pathogenesis of lupus nephritis, outcomes in renal transplantation, and associations with genetic risk factors. This review highlights key developments in our understanding of lupus nephritis over the past decade.",

keywords = "APOL1, Epidemiology, Induction therapy, Kidney, Lupus nephritis, Maintenance therapy, Membranous lupus nephritis, Multitargeted therapy, Mycophenolatemofetil, Proliferative lupus nephritis, Renal transplantation, Rituximab, SLE, Systemic lupus erythematosus, Treatment",

author = "Chen, {Teresa K.} and Fine, {Derek M.}",

note = "Funding Information: Conflict of Interest Teresa K. Chen was the recipient of a research mini-grant award (2012–2013) from the National Kidney Foundation of Maryland. Derek M. Fine has served as a consultant for USB Biosciences.",

year = "2013",

month = sep,

doi = "10.1007/s11926-013-0358-7",

language = "English (US)",

volume = "15",

journal = "Current rheumatology reports",

issn = "1523-3774",

publisher = "Current Science, Inc.",

number = "9",

}

TY - JOUR

T1 - Top 10 developments in lupus nephritis

AU - Chen, Teresa K.

AU - Fine, Derek M.

N1 - Funding Information: Conflict of Interest Teresa K. Chen was the recipient of a research mini-grant award (2012–2013) from the National Kidney Foundation of Maryland. Derek M. Fine has served as a consultant for USB Biosciences.

PY - 2013/9

Y1 - 2013/9

N2 - Lupus nephritis affects up to 60 % of patients with systemic lupus erythematosus and is associated with worse clinical outcomes. Traditionally, it has been treated with high-dose immunosuppression consisting of cyclophosphamide and prednisone; however, recent trials have demonstrated mycophenolate mofetil as a safe and effective alternative for both induction and maintenance of disease. Other progress has been made in our understanding of the pathogenesis of lupus nephritis, outcomes in renal transplantation, and associations with genetic risk factors. This review highlights key developments in our understanding of lupus nephritis over the past decade.

AB - Lupus nephritis affects up to 60 % of patients with systemic lupus erythematosus and is associated with worse clinical outcomes. Traditionally, it has been treated with high-dose immunosuppression consisting of cyclophosphamide and prednisone; however, recent trials have demonstrated mycophenolate mofetil as a safe and effective alternative for both induction and maintenance of disease. Other progress has been made in our understanding of the pathogenesis of lupus nephritis, outcomes in renal transplantation, and associations with genetic risk factors. This review highlights key developments in our understanding of lupus nephritis over the past decade.

KW - APOL1

KW - Epidemiology

KW - Induction therapy

KW - Kidney

KW - Lupus nephritis

KW - Maintenance therapy

KW - Membranous lupus nephritis

KW - Multitargeted therapy

KW - Mycophenolatemofetil

KW - Proliferative lupus nephritis

KW - Renal transplantation

KW - Rituximab

KW - SLE

KW - Systemic lupus erythematosus

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84880399953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880399953&partnerID=8YFLogxK

U2 - 10.1007/s11926-013-0358-7

DO - 10.1007/s11926-013-0358-7

M3 - Article

C2 - 23893235

AN - SCOPUS:84880399953

SN - 1523-3774

VL - 15

JO - Current rheumatology reports

JF - Current rheumatology reports

IS - 9

M1 - 358

ER -

Top 10 developments in lupus nephritis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this